Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer / OncoDaily

oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN

2 months / esmo

NIVOPOST-OP Trial: Postoperative Nivolumab Plus Cisplatin-Based Chemoradiotherapy in High-Risk Locally Advanced Head and Neck Squamous Cell Carcinoma

2 months / oncodaily

Harnessing the microbiome for cancer therapy

2 months / nature

David Sher: 2 Nature Cancer Papers on Tumor Bacterial Burden and Immunotherapy Response

2 months / oncodaily

Global Incidence of Lip, Oral Cavity, and Pharyngeal Cancers – American Cancer Society Journals

2 months / oncodaily

Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer

2 months / oncodaily

Tumor bacteria linked to immunotherapy resistance in head and neck cancer

2 months / medicalxpress

Saturday, January 3, 2026, 11:20 am / permalink 17458 / 7 stories in 2 months



Related Stories



Related Tags


Healthcare

EPA proposes rollback on ethylene oxide sterilizer emissions (30 min)

Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (18 hrs)

more #healthcare


Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (19 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (22 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (34 hrs)

more #pharmaceuticals


Public Health

EPA proposes rollback on ethylene oxide sterilizer emissions (30 min)

Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (21 hrs)

more #publichealth


StackHealth Time Machine



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.